Descriptive Report of Microorganisms Detected in Cultures of COVID-19 Patients Developing Secondary Infection After Tocilizumab Use

Document Type : Original Article

Authors

1 Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

2 Shahid Faghihi Hospital, Shiraz University of Medical Sciences Shiraz, Iran.

3 School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

4 Ophthalmology Department, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

10.30476/tips.2024.103619.1252

Abstract

Tocilizumab an anti-inflammatory medication previously approved for the treatment of rheumatoid arthritis, was widely used during the COVID-19 pandemic. Secondary infections following the use of tocilizumab were expected knowing its inhibitory effect on the cascade of inflammation by blocking IL6. Patterns of microorganism growth in positive culture reports after tocilizumab use have not been widely assessed in the literature. In this retrospective study, we included all patients diagnosed with severe COVID-19 admitted to the intensive care unit (ICU). Patients were divided into two groups; tocilizumab receivers and non-receivers. Patient records were evaluated for the presence of positive culture results. Patterns of microorganism growth and their sensitivity to antibiotics were assessed and compared between the two groups. Seventy-seven patients (74.8%) in the tocilizumab group developed secondary infection, irrespective of the culture origin. The rate of positive culture result was significantly higher in the group treated with tocilizumab (P-value 0.022). Candida and Acinetobacter species were the most common microorganisms detected in sputum cultures, Candida and Escherichia coli (E. coli) species were dominant in urine cultures, and methicillin-resistant Staphylococcus Aureus (MRSA), Acinetobacter and Candida species were the leading microorganisms of positive blood cultures. No significant difference was observed in the culture growth patterns in both groups. The presence of multi-drug resistant nosocomial microorganisms in ICU-admitted COVID-19 patients may be associated with causes other than tocilizumab use and may lead to poor patient outcomes.

Highlights

Dena Firouzabadi (Google Scholar)

Keywords

References

1.    Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020 Oct 6;61(3):E304-E312. doi: 10.15167/2421-4248/jpmh2020.61.3.1530. 
2.    Perisetti A, Goyal H, Gajendran M, Boregowda U, Mann R, Sharma N. Prevalence, Mechanisms, and Implications of Gastrointestinal Symptoms in COVID-19. Front Med (Lausanne). 2020 Oct 30;7:588711. doi: 10.3389/fmed.2020.588711. 3.    Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. J Clin Neurosci. 2020 Jul;77:8-12. doi: 10.1016/j.jocn.2020.05.017. 
4.    Mirmoeeni S, Azari Jafari A, Hashemi SZ, Angouraj Taghavi E, Azani A, Ghasrsaz H, Angouraj Taghavi A, Niksima SH, Rashidi S, Kazemi E, Sheibani H, Naghibi Irvani SS, Dalvand S. Cardiovascular manifestations in COVID-19 patients: A systematic review and meta-analysis. J Cardiovasc Thorac Res. 2021;13(3):181-189. doi: 10.34172/jcvtr.2021.30. 
5.    Abidi E, El Nekidy WS, Alefishat E, Rahman N, Petroianu GA, El-Lababidi R, Mallat J. Tocilizumab and COVID-19: Timing of Administration and Efficacy. Front Pharmacol. 2022 Feb 18;13:825749. doi: 10.3389/fphar.2022.825749. 
6.    The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020. China CDC Wkly. 2020 Feb 21;2(8):113-122. 
7.    Kordzadeh-Kermani E, Khalili H, Karimzadeh I. Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). Future Microbiol. 2020 Sep;15:1287-1305. doi: 10.2217/fmb-2020-0110. 8.    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5.
9.    Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17. PMID: 32303591.
10.    Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021 Jan-Feb;27(1):52-66. doi: 10.1016/j.pulmoe.2020.07.003. 
11.    Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. 
12.    Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020 Apr 14;18(1):164. doi: 10.1186/s12967-020-02339-3. PMID: 32290839; PMCID: PMC7154566.
13.    Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics. 2008 Mar;2(1):75-82. doi: 10.2147/btt.s1828. PMID: 19707430; PMCID: PMC2727785.
14.    Sandhu G, Piraino ST, Piticaru J. Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab. Am J Ther. 2022 May-Jun 01;29(3):e275-e278. doi: 10.1097/MJT.0000000000001487. Epub 2022 Mar 4. PMID: 35249968.
15.    Lang VR, Englbrecht M, Rech J, Nüsslein H, Manger K, Schuch F, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford). 2012 May;51(5):852-7. doi: 10.1093/rheumatology/ker223. 
16.    Viswanatha GL, Anjana Male CKVLSN, Shylaja H. Efficacy and safety of tocilizumab in the management of COVID-19: a systematic review and meta-analysis of observational studies. Clin Exp Rheumatol. 2022 Mar;40(3):634-646. doi: 10.55563/clinexprheumatol/4dg0or. 
17.    Karimzadeh I, Mirzaee M, Sadeghimanesh N, Sagheb MM. Antimicrobial resistance pattern of Gram-positive bacteria during three consecutive years at the nephrology ward of a tertiary referral hospital in Shiraz, Southwest Iran. J Res Pharm Pract. 2016 Oct-Dec;5(4):238-247. doi: 10.4103/2279-042X.192460. 
18.    Karimzadeh I, Sadeghimanesh N, Mirzaee M, Sagheb MM. Evaluating the resistance pattern of gram-negative bacteria during three years at the nephrology ward of a referral hospital in southwest of Iran. J Nephropathol. 2017 Jul;6(3):210-219. doi: 10.15171/jnp.2017.35. 
19.    Ignatius EH, Wang K, Karaba A, Robinson M, Avery RK, Blair P, et al. Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. Open Forum Infect Dis. 2020 Dec 28;8(1):ofaa598. doi: 10.1093/ofid/ofaa598. 
20.    Moore JL, Stroever SJ, Rondain PE, Scatena RN. Incidence of Secondary Bacterial Infections Following Utilization of Tocilizumab for the Treatment of COVID-19 - A Matched Retrospective Cohort Study. J Glob Infect Dis. 2021 Mar 22;13(2):67-71. doi: 10.4103/jgid.jgid_358_20. 21.    Minihan B, McAuliffe E, Powell J, Wong SL, Wilkie K, Murphy C, et al. Association between tocilizumab treatment of hyperinflammatory patients with COVID-19 in a critical care setting and elevated incidence of hospital-acquired bacterial and invasive fungal infections. J Hosp Infect. 2022 Aug;126:29-36. doi: 10.1016/j.jhin.2022.04.007. 
22.    Moreno-Torres V, de Mendoza C, de la Fuente S, Sánchez E, Martínez-Urbistondo M, Herráiz J, et al. Bacterial infections in patients hospitalized with COVID-19. Intern Emerg Med. 2022 Mar;17(2):431-438. doi: 10.1007/s11739-021-02824-7. 
23.    Shah R, Shah J, Gohil J, Revathi G, Surani S. Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya. Int J Gen Med. 2022 Mar 3;15:2415-2425. doi: 10.2147/IJGM.S356547. 
24.    Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020 Aug;2(8):e474-e484. 
25.    Rana MA, Chachar AZK, Zartash S, Siddiqui MH, Naqvi SMA, Javed M, et al. Post tocilizumab secondary infections in COVID-19 patients—are we doing enough. Pakistan J Med Health Sci. 2021;15:2023-6.
26.    Barahimi E, Defaee S, Shokraei R, Sheybani-Arani M, Salimi Asl A, Ghaem HM. Bacterial endocarditis following COVID-19 infection: two case reports. J Med Case Rep. 2023 Jun 16;17(1):274. doi: 10.1186/s13256-023-03970-6. 
27.    Singh N, Puri S, Anshul, Kumar S, Pahuja H, Kalia R, et al. Risk Factors and Outcome Analysis of Gram-Positive Bacteremia in Critically Ill Patients. Cureus. 2023 Mar 23;15(3):e36585.
28.    Hill JA, Menon MP, Dhanireddy S, Wurfel MM, Green M, Jain R, et al. Tocilizumab in hospitalized patients with COVID-19: Clinical outcomes, inflammatory marker kinetics, and safety. J Med Virol. 2021 Apr;93(4):2270-2280. doi: 10.1002/jmv.26674. 
Trends in Pharmaceutical Sciences
Volume 10, Issue 3
September 2024
Pages 241-250

Files

Share

How to cite

Statistics